バセドウ病放射性ヨウ素内用療法におけるヨウ化カリウムにおける前処置に関する後向き観察研究 by 橘 正剛
Articles © The authors   |   Journal compilation © J Endocrinol Metab and Elmer Press Inc™   |   www.jofem.org
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
25
Original Article J Endocrinol Metab. 2017;7(1):25-30
ressElmer 
Evaluation of the Efficacy of Potassium Iodide Preparation 
for Radioactive Iodine Therapy in Graves’ Disease: A 
Retrospective Chart Review
Seigo Tachibanaa, b, d, Hiroyuki Yamashitac, Toshihiko Yanaseb
Abstract
Background: Pretreatment by antithyroid drugs (ATDs) before ra-
dioactive iodine therapy (RAIT) for Graves’ disease (GD) is often 
performed to avoid aggravation of thyroid function including thyroid 
storm. However, in patients suffering from adverse effects of ATDs, 
potassium iodide (KI) is often selected to treat hyperthyroidism be-
fore RAIT in Japan. The aim of this study was to evaluate the ef-
ficacy of KI preparation for RAIT in GD and whether a short-term 
discontinuation of KI before RAIT is a safe and useful method in GD 
patients showing adverse effects from ATDs.
Methods: This is a retrospective chart review. The 24 patients en-
rolled in this study were divided into two groups. Patients who had 
large goiter and/or underwent previous RAIT were excluded. Before 
RAIT, 11 patients were administered KI and were referred to as the 
KI group. The remaining 13 patients were administered methima-
zole (MMI) and referred to as the MMI group. Between these two 
groups, the following factors were compared; radioactive iodine up-
take (RAIU) before RAIT, thyroid gland weight, dose of administered 
131-I, dose of 131-I based on thyroid gland weight, free thyroxine 
(FT4) at RAIT, difference in FT4 between before and 4 days after dis-
continuation of drugs, and thyroid function and thyroid gland weight 
1 year after RAIT.
Results: RAIU before RAIT (P = 0.0018), dose of 131-I (P = 0.0037), 
FT4 at RAIT (P = 0.0034), and thyroid gland weight 1 year after 
RAIT (P = 0.0065) showed significant differences. Thyroid gland 
weight, dose of 131-I based on thyroid gland weight, difference in 
FT4 between before drug discontinuation and at RAIT, and thyroid 
function at 1 year after RAIT did not show any significant differences.
Conclusion: These results suggest that most patients without large 
goiter and/or highly aggressive disease may be safely and efficiently 
treated with RAIT and KI pretreatment until 4 days before therapy.
Keywords: Graves’ disease; Radioactive iodine therapy; Potassium 
iodide; Antithyroid drug
Introduction
Radioactive iodine therapy (RAIT) is one effective treatment 
for Graves’ disease (GD). RAIT for GD was first introduced 
approximately 70 years ago, and the utility of this procedure is 
well known [1]. In Japan, the first choice for GD treatment is an 
antithyroid drug (ATD); however, when patients show adverse 
ATD effects, and/or GD does not go into remission with ATDs, 
RAIT and thyroidectomy are the second treatment options [2]. 
Endocrinologists try to treat hyperthyroidism by ATDs and/or 
potassium iodide (KI) before RAIT to prevent thyroid storm 
after RAIT. Burch et al reported that among 709 survey re-
spondents who were endocrinologists, 352 (49.6%) used ATD 
preparations only in selected patients and 37.7% did routinely 
in most patients [3]. Their report indicated that not only iodine 
restriction before RAIT, but also discontinuation of ATDs is of-
ten selected in numerous cases. As well as cases administered 
ATDs, when a patient is taking KI for the treatment of adverse 
ATD effects, KI should be discontinued before RAIT. Howev-
er, discontinuation of ATD and/or KI is one of the risk factors 
of thyroid function aggravation accompanying RAIT. In order 
to avoid this risk, Zakavi et al evaluated methimazole (MMI) 
discontinuation before RAIT and reported that a short duration 
of ATD withdrawal before RAIT is safe and useful [4]. In fact, 
in the above Burch survey, 37.1% of the responders stopped 
ATDs at 7 days, 25.2% at 5 days, 12.1% at 4 days, and 15.8% 
at 3 days before RAIT [3]. On the other hand, very few stud-
ies have focused on a short duration of KI withdrawal before 
RAIT. In several countries, KI administration for GD is not 
recommended except in preparation for GD surgery, treatment 
for thyroid storm, or treatment after RAIT [5-11]. However, in 
Japan, a high-iodine-intake area, KI is reported as a useful drug 
for GD treatment. Hirakawa et al reported that restriction of di-
etary iodine does not ameliorate the early effects of ATDs in an 
area of excessive iodine intake [12]. Takata et al demonstrated 
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the usefulness of KI combined with ATD therapy [13]. In addi-
tion, Okamura et al reported the effectiveness of only KI in GD 
patients who showed adverse effects to MMI [14]. Therefore, in 
Japan, KI is often administered to GD patients who are showing 
adverse ATD effects. In addition, when GD patients showing 
adverse ATD effects are treated by RAIT, KI is often selected to 
avoid aggravation of thyroid function.
Materials and Methods
Objective
In this study, we evaluated preparation for RAIT by KI, and 
whether a short duration of KI withdrawal before RAIT is a 
safe and useful method in GD patients.
Subjects
RAIT was performed in 56 GD patients from May 2011 to Oc-
tober 2014 in our institution. Of the 56 patients, 24 were en-
rolled in this study. Thirty-two patients were excluded, because 
they dropped out after RAIT or RAIT was not performed in ac-
cordance with the following protocol and/or exclusion criteria. 
The exclusion criteria were defined as follows: large goiter and/
or experience of previous RAIT. The definition of large goiter 
in exclusion criteria was determined that estimated thyroid 
gland weight was more than 50 g. In Japan, a single adminis-
tered dose of 131-I RAIT for outpatients is restricted to within 
13 mCi. If patients have large goiter, it is difficult to evaluate 
the efficacy of single RAIT because an enough high dose of 
131-I to treat hyperthyroidism cannot be administered. There-
fore, in this study, we determined the above exclusion criteria 
of thyroid gland weight. All enrolled patients were diagnosed 
with GD by thyrotoxicosis with positive thyroid stimulating 
hormone receptor antibody (TRAb) and/or high radioactive io-
dine uptake (RAIU). Neck ultrasonography was performed in 
all patients to exclude patients with an autonomously function-
ing thyroid nodule and possible malignant tumor. All patients 
were treated with RAIT for the following reasons. Of the 24 pa-
tients, 10 showed adverse effects from ATDs: four showed liver 
dysfunction, four showed drug eruption, one showed arthralgia, 
one showed drug fever, and two showed agranulocytosis. Some 
patients experienced multiple adverse effects at the same time. 
Thirteen were unable to go into remission with ATDs, and one 
chose RAIT. For the preparation of RAIT, 11 patients were ad-
ministered KI, and 13 were administered MMI. The dose of 
drugs before RAIT is shown in Table 1.
Protocol of RAIT
Before RAIU for RAIT, oral-iodine-intake was restricted for 7 
days in patients treated with only ATDs, and for 4 days in those 
treated with KI. MMI and KI were withdrawn 4 days before 
RAIU for RAIT. Duration of restriction of oral-iodine-intake 
and discontinuation of MMI or KI was adopted according to 
the guidelines for RAIT from Japan Thyroid Association (JTA) 
in 2007 [15]. RAIU was evaluated 3 h after intake of 131-I at a 
dose of 0.1 mCi. The dose of administered 131-I was 13.0 mCi 
as the fixed dose or the calculated dose. The determination of 
the fixed dose or the calculated dose of 131-I was by doctor’s 
decision in consideration of the patient clinical background. 
For example, if the patient had relatively large goiter and/or 
could not take ATDs because of adverse effects, the fixed dose 
method was often selected, because immediate treatment of 
hyperthyroidism was preferred. The calculated dose was deter-
mined by the following formula [16]: calculated dose (mCi) = 
(thyroid gland weight (g)) × (80 - 160 μCi 131-I/g of thyroid)/
(RAIU (%)) × 10. The dose of 131-I based on thyroid gland 
weight was determined between 80 and 160 μCi/g. If a euthy-
roid state was expected after RAIT, the dose of 131-I based 
on thyroid gland weight was determined between 80 and 120 
μCi/g. However, if hypothyroidism was acceptable after RAIT, 
it was determined between 140 and 160 μCi/g. Thyroid gland 
weight was estimated by thyroid US. After RAIT, discontinua-
tion of MMI or KI, and iodine restriction continued for 3 days.
Methods
This was a retrospective chart review. The 24 enrolled patients 
Table 1.  Clinical Features of KI and MMI Groups
KI MMI P-value
Age (mean ± SD) 41.9 ± 11.4 39.2 ± 13.6 n.s.
Gender (male/female) 2:9 0:13 n.s.
Smoking (yes/no) 3:8 2:11 n.s.
Duration of GD treatment (median (25-75%)), months 16.0 (3.0 - 52.0) 37.0 (16.5 - 58.5) n.s.
FT4 before discontinuation of KI or MMI (median (25-75%)), ng/dL 2.11 (1.58 - 2.48) 1.21 (1.00 - 1.49) P < 0.05
Method of RAIT (fixed dose/calculated dose) 8:3 3:10 P < 0.05
Dose of drugs before RAIT, (median (25-75%)), mg -
  MMI (n = 0:13) - 12.5 (7.5 - 16.3)
  KI (n = 11:0) 150 (100 - 200) -
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were divided into the following two groups. Before RAIT, KI 
was administered to 11 patients (two male and nine female) 
who were referred to as the KI group, and MMI was adminis-
tered to 13 female patients who were referred to as the MMI 
group. The clinical features of these two groups are shown in 
Table 1.
Between these two groups, we compared the following 
factors: RAIU before RAIT, thyroid gland weight, dose of ad-
ministered 131-I, dose of 131-I based on thyroid gland weight, 
free thyroxine (FT4) at RAIT, variation of FT4 between before 
and at 4 days after discontinuation of drugs, thyroid function 
at 1 year after RAIT and thyroid gland weight at 1 year after 
RAIT. The thyroid function at 1 year after RAIT was evaluated 
on the basis of whether each subject was taking MMI or KI 1 
year after RAIT or not. Patients who were taking MMI or KI 
were defined as non-remissive (non-R), and patients who were 
not taking both MMI and KI were defined as in remission (R). 
The protocol of this study is shown in Figure 1.
Laboratory measurements
Serum levels of thyroid stimulating hormone (TSH), FT4 and 
TRAb were determined using an ECLusys kit (Roche Diag-
nostics, Penzberg, Germany). The reference ranges were as 
follows: TSH 0.5 - 5.0 mIU/L and FT4 0.9 - 1.7 ng/dL. TRAb 
measurement was determined with the anti-M22 antibody, 
third generation. The reference range of TRAb was below 2.0 
IU/L.
Ethics approval
Approval to undertake the study was received from the Re-
search Ethics Committee in Yamashita Thyroid and Parathy-
roid Clinic (2016-2).
Statistical analysis
In these two groups, statistical analysis was performed with 
Fisher’s exact test and the Mann-Whitney U test using JMP 
ver. 11.0 (SAS Institute Inc.).
Results
There were significant statistical differences in RAIU before 
RAIT, dose of 131-I, FT4 at RAIT, and thyroid gland weight at 
1 year after RAIT between the KI group and MMI group (Ta-
ble 2). There were no significant differences in thyroid gland 
weight, dose of 131-I based on thyroid gland weight, differ-
ence in FT4 between before and 4 days after discontinuation 
of drugs, and thyroid function at 1 year after RAIT between the 
KI group and MMI group (Table 2). RAIU of the KI group was 
lower than that of the MMI group, approximately half of the 
Figure 1. The protocol of this study. 
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RAIU of the MMI group was equivalent to that of the KI group 
(P = 0.0018). The 131-I administration dose of the KI group 
was higher than that of the MMI group (P = 0.0037). Thyroid 
gland weight and dose of 131-I based on thyroid gland weight 
of the KI group was equivalent to the MMI group (P = 0.1396, 
P = 0.8393). FT4 at RAIT in the KI group was higher than that 
in the MMI group (P = 0.0034). However, difference in FT4 
between before and 4 days after discontinuation of drugs of the 
KI group was slightly higher than that of the MMI group, but 
it was not significant (P = 0.1557). Regarding thyroid function 
at 1 year after RAIT, the “R” rate of the KI group was slightly 
higher than that of the MMI group, but it was not significant (P 
= 0.0932). Thyroid gland weight at 1 year after RAIT of the KI 
group was lower than that of the MMI group (P = 0.0065). The 
dose of drugs at 1 year after RAIT was added as supplementary 
data in Table 2.
Discussion
In Japan, RAIT is the second or third choice for GD treatment 
[2]. However, institutions carrying out RAIT have been gradu-
ally increasing. Therefore, when patients show adverse effects 
of ATDs or cannot go into remission by ATDs, RAIT or thy-
roidectomy is often chosen. Thyrotoxicosis is one of the signif-
icant complications associated with RAIT. Not only transient 
exacerbation of thyrotoxicosis, but also thyroid storm has been 
reported [17-19]. To reduce such risks, ATDs are administered 
in preparation for RAIT in Japan. In addition, in patients who 
show adverse effects of ATDs or whose hyperthyroidism can-
not be controlled by only ATDs, KI is also often administered 
as a treatment before RAIT. In fact, Zakavi et al reported that a 
shorter discontinuation of MMI before RAIT did not influence 
the effects of RAIT and may be preferable in most patients 
[4]. On the other hand, the influence on RAIT of KI discon-
tinuation before RAIT was seldom reported. Some reports rec-
ommended lithium administration as a pretreatment for RAIT 
[20]. However, administration of lithium for hyperthyroidism 
is an off-label prescription in Japan. Therefore, it is difficult 
to routinely administer lithium to GD patients suffering from 
adverse effects of ATDs. According to the guidelines for RAIT 
from JTA in 2007, the KI discontinuation 3 - 4 days in prior to 
RAIT is effective. However, the data and/or literature support-
ing this were not available in the guidelines [15]. Therefore, in 
this study, we collected the data of GD patients who were pre-
pared for RAIT with KI and evaluated whether a short duration 
of KI discontinuation before RAIT is a safe and useful method 
in GD patients showing adverse ATD effects.
The significantly lower RAIU of the KI group compared 
with that of the MMI group (Table 2) suggests that a 4-day dis-
continuation of KI may not be sufficient for adequate RAIU. 
Hiraiwa et al reported that RAIU of Japanese GD patients 
without iodine restriction was 42.4±17.6% (SD) [21]. In our 
study, KI was administered at a median dose of 150 mg in the 
KI group and hyperthyroidism was considerably treated before 
RAIT. High doses of iodine suppress RAIU and thyroid hor-
mone secretion [22, 23]. Therefore, RAIU before KI discon-
tinuation may have been suppressed by the above administered 
dose of iodine, and a 4-day discontinuation of KI contributed 
to improve RAIU to that equivalent of Japanese GD patients 
without iodine restriction.
Thyroid gland weight did not show significant difference 
between KI and MMI group, but that of the KI group was 
slightly lower than that of the MMI group. Therefore, in the 
KI group, although the RAIU was lower than that of the MMI 
group, the dose of 131-I based on thyroid gland weight was 
equivalent to that of the MMI group. According to Beierwal-
tes’ reports, the dose of 131-I based on thyroid gland weight 
in both groups was adequate to treat hyperthyroidism [16]. 
Thyroid function tests at 1 year after RAIT did not show sig-
nificant statistical difference between the KI and MMI groups. 
However, the “R” rate of the KI group was slightly higher 
than that of the MMI group. The result associated with thyroid 
gland weight at 1 year after RAIT was also consistent with 
this result. There were many patients who could not go into 
remission with ATDs in the MMI group; however, almost all 
Table 2.  Results of This Study
KI MMI P-value
RAIU (median (25-75%)), % 29.9 (20.9 - 32.6) 62.9 (55.6 - 72.3) 0.0018*
Thyroid gland weight (median (25-75%)), g 24.1 (16.9 - 32.2) 32.7 (23.5 - 42.2) 0.1396
Dose of 131-I (median (25-75%)), mCi 13.0 (10.9 - 13.0) 7.5 (5.5 - 11.9) 0.0037*
Dose of 131-I based on thyroid gland weight 
(median (25-75%)), μCi/g
144.8 (121.8 - 176.6) 156.9 (118.7 - 193.9) 0.8393
FT4 at RAIT (median (25-75%)), ng/dL 2.25 (1.79 - 4.02) 1.47 (0.89 - 1.69) 0.0034*
Difference in FT4 between before drug discontinuation and at RAIT  
(median (25-75%)), ng/dL
0.54 (-0.05 - 1.70) 0.08 (-0.34 - 0.49) 0.1557
Thyroid function at 1 year after RAIT (R/non-R) 8:3 5:8 0.0932
Thyroid gland weight at 1 year after RAIT (median (25-75%)), g 5.3 (3.2 - 6.4) 8.9 (6.7 - 12.5) 0.0065*
Dose of drugs at 1 year after RAIT (median (25-75%)), mg
  MMI (n = 0:13) - 2.5 (0 - 5)
  KI (n = 11:0) 0 (0-25) -
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patients showed adverse effects from ATDs in the KI group. 
The differences in aggressiveness and/or resistance to ATDs 
between the two groups may have contributed to the differ-
ence in the “R” rate. Therefore, it may be difficult to demon-
strate the efficiency of preparation for RAIT by KI with MMI 
group comparison. However, our results demonstrated that GD 
patients without large goiter and/or highly aggressive disease 
could achieve a good outcome with KI preparation for RAIT.
Regarding thyroid function after a 4-day discontinuation 
of KI, FT4 in the KI group was higher than that in the MMI 
group. It is well known that the effects of KI in GD often di-
minish during administration, described as the “escape phe-
nomenon” [24]. However, Okamura et al reported that many 
GD patients who were treated with KI continuously for a long 
duration went into remission in Japan [14]. We continued KI 
treatment for GD patients unless they had significant hyperthy-
roidism and almost all patients in the KI group showed mild 
hyperthyroxinemia. This background may explain the higher 
FT4 at RAIT in the KI group than that in the MMI group. 
However, the difference in FT4 between before and after drug 
discontinuation was not significant between the two groups, 
suggesting that the influence of the 4-day discontinuation of KI 
on aggravation of thyroid function was equivalent to that of the 
4-day discontinuation of MMI.
Conclusion
In the present study, our results suggested that preparation for 
RAIT by KI predicted a good RAIT outcome, and that a 4-day 
discontinuation of KI before RAIT is a useful and safe proce-
dure to avoid RAIT-associated thyroid function deterioration. 
In conclusion, RAIT can be performed safely by discontinuing 
KI 4 days before the treatment and can achieve a good out-
come in GD patients without large goiter and/or highly aggres-
sive disease.
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